|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
DiSilvestro PA, Ali S, Craighead PS, Lucci
JA, Lee YC, Cohn DE, Spirtos NM, Tewari KS, Muller C, Gajewski WH,
et al: Phase III randomized trial of weekly cisplatin and
irradiation versus cisplatin and tirapazamine and irradiation in
stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to
the pelvis: A Gynecologic Oncology Group study. J Clin Oncol.
32:458–464. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Friedlander M and Grogan M: U.S.
Preventative Services Task Force: Guidelines for the treatment of
recurrent and metastatic cervical cancer. Oncologist. 7:342–347.
2002.PubMed/NCBI
|
|
4
|
Travis LB, Fossa SD, Sesso HD, Frisina RD,
Herrmann DN, Beard CJ, Feldman DR, Pagliaro LC, Miller RC, Vaughn
DJ, et al: Chemotherapy-induced peripheral neurotoxicity and
ototoxicity: New paradigms for translational genomics. J Natl
Cancer Inst. 106:pii: dju0442014. View Article : Google Scholar
|
|
5
|
Chen SJ, Kuo CC, Pan HY, Tsou TC, Yeh SC
and Chang JY: Mechanistic basis of a combination D-penicillamine
and platinum drugs synergistically inhibits tumor growth in
oxaliplatin-resistant human cervical cancer cells in vitro and in
vivo. Biochem Pharmaco. l95:28–37. 2015. View Article : Google Scholar
|
|
6
|
Li CJ, Xu YM and Sun YL: Research on
anti-cervical cancer component of Pinellia pedatisecta Schott. J
Shanghai Med Univ. 8:421–423. 1981.(In Chinese).
|
|
7
|
Chemistry Department of Basic Research
Center, Obstetrics and Gynecology Hospital, . Research of Pinellia
pedatisecta Schott on cervical cancer. Shanghai Med J. 1:13–16.
1978.(In Chinese).
|
|
8
|
Li GL, Jiang W, Xia Q, Chen SH, Ge XR, Gui
SQ and Xu CJ: HPV E6 down-regulation and apoptosis induction of
human cervical cancer cells by a novel lipid-soluble extract (PE)
from Pinellia pedatisecta Schott in vitro. J Ethnopharmacol.
132:56–64. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li GL, Gui SQ, Zhu DH, Chen SH and Ye Y:
Effects of pinellia extraction only or combined with cisplatin on
growth of HeLa cells of cervical cancer. Fudan Univ J Med Sci.
34:869–872. 2007.
|
|
10
|
Spielmann H: FRAME Annual Lecture.
International co-operation: An essential requirement for replacing
animal toxicity tests. Altern Lab Anim. 29:637–648. 2001.PubMed/NCBI
|
|
11
|
Hatok J and Racay P: Bcl-2 family
proteins: Master regulators of cell survival. Biomol Concepts.
7:259–270. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Matt S and Hofmann TG: The DNA
damage-induced cell death response: A roadmap to kill cancer cells.
Cell Mol Life Sci. 73:2829–2850. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Harlan LC and Warren JL: Global survival
patterns: Potential for cancer control. Lancet. 385:926–928. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shi JF, Canfell K, Lew JB and Qiao YL: The
burden of cervical cancer in China: Synthesis of the evidence. Int
J Cancer. 130:641–652. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Allemani C, Weir HK, Carreira H, Harewood
R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A,
et al: Global surveillance of cancer survival 1995–2009: Analysis
of individual data for 25,676,887 patients from 279
population-based registries in 67 countries (CONCORD-2). Lancet.
385:977–1010. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ferlay J, Forman D, Mathers CD and Bray F:
Breast and cervical cancer in 187 countries between 1980 and 2010.
Lancet. 379:1390–1391. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jelavić TB, Miše BP, Strikic A, Ban M and
Vrdoljak E: Adjuvant chemotherapy in locally advanced cervical
cancer after treatment with concomitant chemoradiotherapy-room for
improvement? Anticancer Res. 35:4161–4165. 2015.PubMed/NCBI
|
|
18
|
Penson RT, Huang HQ, Wenzel LB, Monk BJ,
Stockman S, Long HJ III, Ramondetta LM, Landrum LM, Oaknin A, Reid
TJ, et al: Bevacizumab for advanced cervical cancer:
Patient-reported outcomes of a randomised, phase 3 trial (NRG
Oncology-Gynecologic Oncology Group protocol 240). Lancet Oocol.
16:301–311. 2015. View Article : Google Scholar
|
|
19
|
Sprowl JA, Lancaster CS, Pabla N, Hermann
E, Kosloske AM, Gibson AA, Li L, Zeeh D, Schlatter E, Janke LJ, et
al: Cisplatin-induced renal injury is independently mediated by
OCT2 and p53. Clin Cancer Res. 20:4026–4035. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Karasawa T and Steyger PS: An integrated
view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol
Lett. 237:219–227. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hirchaud F, Hermetet F, Ablise M,
Fauconnet S, Vuitton DA, Prétet JL and Mougin C: Isoliquiritigenin
induces caspase-dependent apoptosis via downregulation of HPV16 E6
expression in cervical cancer Ca Ski cells. Planta Med.
79:1628–1635. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Peng Y, Guo CS, Li PX, Fu ZZ, Gao LM, Di
Y, Ju YK, Tian R and Xue JJ: Immune and anti-oxidant functions of
ethanol extracts of Scutellaria baicalensis Georgi in mice bearing
U14 cervical cancers. Asian Pac J Cancer Prev. 15:4129–4133. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang LH, Li Y, Yang SN, Wang FY, Hou Y,
Cui W, Chen K, Cao Q, Wang S, Zhang TY, et al: Gambogic acid
synergistically potentiates cisplatin-induced apoptosis in
non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1
signalling. Br J Cancer. 110:341–352. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li X, Huang T, Jiang G, Gong W, Qian H and
Zou C: Synergistic apoptotic effect of crocin and cisplatin on
osteosarcoma cells via caspase induced apoptosis. Toxicol Lett.
221:197–204. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen Y, Liu JM, Xiong XX, Qiu XY, Pan F,
Liu D, Lan SJ, Jin S, Yu SB and Chen XQ: Piperlongumine selectively
kills hepatocellular carcinoma cells and preferentially inhibits
their invasion via ROS-ER-MAPKs-CHOP. Oncotarget. 6:6406–6421.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tan S, de Vries EG, van der Zee AG and de
Jong S: Anticancer drugs aimed at E6 and E7 activity in
HPV-positive cervical cancer. Curr Cancer Drug Targets. 12:170–184.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Münger K, Scheffner M, Huibregtse JM and
Howley PM: Interactions of HPV E6 and E7 oncoproteins with tumour
suppressor gene products. Cancer Surv. 12:197–217. 1992.PubMed/NCBI
|
|
28
|
Bradner JE: Cancer: An essential passenger
with p53. Nature. 520:626–627. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Guimarães-Camboa N, Stowe J, Aneas I,
Sakabe N, Cattaneo P, Henderson L, Kilberg MS, Johnson RS, Chen J,
McCulloch AD, et al: HIF1α represses cell stress pathways to allow
proliferation of hypoxic fetal cardiomyocytes. Dev Cell.
33:507–521. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee D, Kwon JH, Kim EH, Kim ES and Choi
KY: HMGB2 stabilizes p53 by interfering with E6/E6AP-mediated p53
degradation in human papillomavirus-positive HeLa cells. Cancer
Lett. 292:125–132. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang W, Liu Y, Zhao N, Chen H, Qiao L,
Zhao W and Chen JJ: Role of Cdk1 in the p53-independent abrogation
of the postmitotic checkpoint by human papillomavirus E6. J Virol.
89:2553–2562. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kochetkov DV, Il'Inskaia GV, Komarov PG,
Strom E, Agapova LS, Ivanov AV, Budanov AV, Frolova EI and Chumakov
PM: Transcriptional inhibition of human papilloma virus in cervical
carcinoma cells reactivates functions of the tumor suppressor p53.
Mol Biol (Mosk). 41:515–523. 2007.(In Russian). View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Münger K and Howley PM: Human
papillomavirus immortalization and transformation functions. Virus
Res. 89:213–228. 2002. View Article : Google Scholar : PubMed/NCBI
|
